NEW YORK (GenomeWeb News) - BioSeek said today it has entered into an agreement with the Belgian biopharmaceutical company UCB to evaluate drug compounds.
Under the agreement, BioSeek will use its BioMAP systems to support target differentiation, lead development, and drug-candidate selection activities for UCB compounds in several target classes. UCB is focused on developing therapeutics for central nervous system disorders, inflammation, and oncology.
The BioMAP systems are a series of primary cell-based assay systems used to replicate cell and pathway interactions involved in human disease.
Financial terms of the agreement were not released.